GlassScriptPhysician profile
Marisa C Chang
NPI 1730348269
$30,599.12
in general payments reported to CMS, 2019-2025
81 companies · $9,360 in 2025
The $9,360 reported for 2025 was more than what 89% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,185 · 2020: $3,180 · 2021: $3,334 · 2022: $3,154 · 2023: $4,179 · 2024: $4,206 · 2025: $9,360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Long Term Medical Supply Or Device Loan: $4,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,977.34 |
| Long Term Medical Supply Or Device Loan | $4,768.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| International Rehabilitative Sciences, INC | $4,834.63 | 2025 | Rs-4i Plus With Intersperse, Rs-Lbg, Rs-Fbg |
| Abbvie INC. | $3,886.51 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Lundbeck LLC | $1,725.83 | 2019-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $1,428.91 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Ucb, INC. | $1,252.47 | 2020-2025 | Zilbrysq, Briviact, Rystiggo |
| Lilly USA, LLC | $1,241.15 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Csl Behring | $1,138.49 | 2019-2025 | Hizentra |
| Pfizer INC. | $1,042.98 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $913.35 | 2019-2025 | |
| Amgen INC. | $854.95 | 2019-2021 | |
| Merz Pharmaceuticals, LLC | $807.72 | 2021-2025 | Xeomin, Inbrija |
| Allergan, INC. | $541.22 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $525.03 | 2019-2025 | Dysport |
| Jazz Pharmaceuticals INC. | $521.89 | 2019-2025 | Xywav |
| Biogen, INC. | $493.89 | 2020-2025 | Leqembi, Vumerity, Tysabri |
Show all 81 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marisa Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.